Patrick W Smith
CIK 1167028 · CHIEF EXECUTIVE OFFICER · last filed 2026-09-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AXON price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 2-411
SCOTTSDALE, AZ 85259
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AXON | CHIEF EXECUTIVE OFFICER | 3,119,242 | $315.68 | $984.68M | -$632.72M | 48 | 2026-09-10 |
| Insight Molecular Diagnostics Inc. (OCX) Delisted | 10%+ Owner | 2,872,671 | $3.20 | $9.19M | $2.45M | 5 | 2025-02-11 |
| AXON ENTERPRISE, INC. (AAXN) Delisted | CHIEF EXECUTIVE OFFICER | 370,310 | — | — | -$67.10M | 21 | 2020-12-23 |
Recent Filings · Page 4 of 14
132 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-26 | AXON | Grant (A) | +194,030 | $0 | EDGAR |
| 2025-02-11 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Mixed | +1,463,414 | $3.00M | EDGAR |
| 2025-02-04 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +915 | $1.8K | EDGAR |
| 2025-01-31 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +4,198 | $8.4K | EDGAR |
| 2025-01-15 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +16,055 | $34.1K | EDGAR |
| 2024-12-27 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +90,219 | $192.2K | EDGAR |
| 2024-12-17 | AXON | Gift (G) | −45,108 | $0 | EDGAR |
| 2024-10-04 | AXON | Sell (S) | −4,767 | -$1.93M | EDGAR |
| 2024-10-02 | AXON | Notice (144) | −117,707 | -$46.99M | EDGAR |
| 2024-10-02 | AXON | Mixed | +5,000 | $1.84M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.